当前位置: 首页 >> 检索结果
301. Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
作者: Lien T Quach.;Bei-Hung Chang.;Mary T Brophy.;Soe Soe Thwin.;Keri Hannagan.;James R O'Dell.
来源: Rheumatology (Oxford). 2017年56卷3期378-383页
The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial.
302. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
作者: Rohit Aggarwal.;Priyadarshini Loganathan.;Diane Koontz.;Zengbiao Qi.;Ann M Reed.;Chester V Oddis.
来源: Rheumatology (Oxford). 2017年56卷2期247-254页
The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM.
303. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.
作者: Lesley-Anne Bissell.;Elizabeth M A Hensor.;Lukasz Kozera.;Sarah L Mackie.;Agata N Burska.;Jacqueline L Nam.;Helen Keen.;Edith Villeneuve.;Helena Donica.;Maya H Buch.;Philip G Conaghan.;Jacqueline Andrews.;Paul Emery.;Ann W Morgan.
来源: Rheumatology (Oxford). 2016年55卷12期2181-2190页
To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
304. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
作者: Pascal H P de Jong.;Johanna M Hazes.;Leander R Buisman.;Pieternella J Barendregt.;Derkjen van Zeben.;Peter A van der Lubbe.;Andreas H Gerards.;Mike H de Jager.;Peter B J de Sonnaville.;Bernard A Grillet.;Jolanda J Luime.;Angelique E A M Weel.
来源: Rheumatology (Oxford). 2016年55卷12期2138-2147页
To evaluate direct and indirect costs per quality adjusted life year (QALY) for different initial treatment strategies in very early RA.
305. Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
作者: Bruce Kirkham.;Khaldoun Chaabo.;Christopher Hall.;Toby Garrood.;Timothy Mant.;Elizabeth Allen.;Alexandra Vincent.;Joana C Vasconcelos.;Andrew T Prevost.;Gabriel S Panayi.;Valerie M Corrigall.
来源: Rheumatology (Oxford). 2016年55卷11期1993-2000页
Binding immunoglobulin protein (BiP) is a human endoplasmic reticulum-resident stress protein. In pre-clinical studies it has anti-inflammatory properties due to the induction of regulatory cells. This randomized placebo-controlled, dose ascending double blind phase I/IIA trial of BiP in patients with active RA, who had failed accepted therapies, had the primary objective of safety. Potential efficacy was measured by DAS28-ESR and changes in biomarkers.
306. The relevance of performing exercise test before starting supervised physical exercise in asymptomatic cardiovascular patients with rheumatic diseases.
作者: Bárbara Nascimento de Carvalho Klemz.;Edgard Torres Dos Reis-Neto.;Fábio Jennings.;Usmary Sardinha Siqueira.;Fábio Kadratz Klemz.;Helder Henrique Costa Pinheiro.;Emília Inoue Sato.;Jamil Natour.;Vera Lúcia Szejnfeld.;Marcelo de Medeiros Pinheiro.
来源: Rheumatology (Oxford). 2016年55卷11期1978-1986页
To evaluate the impact and risk factors associated with an abnormal exercise test (ET) in systemic inflammatory rheumatic disease (SIRD) patients before commencing supervised physical exercise.
307. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment.
作者: Glen S Hazlewood.;Claire Bombardier.;George Tomlinson.;Carter Thorne.;Vivian P Bykerk.;Andrew Thompson.;Diane Tin.;Deborah A Marshall.
来源: Rheumatology (Oxford). 2016年55卷11期1959-1968页
To quantify the preferences of patients with early RA (ERA) with the benefits and harms of DMARDs.
308. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
作者: Joachim Sieper.;Martin Rudwaleit.;Jan Lenaerts.;Jürgen Wollenhaupt.;Leysan Myasoutova.;Sung-Hwan Park.;Yeong W Song.;Ruji Yao.;Susan Huyck.;Marinella Govoni.;Denesh Chitkara.;Nathan Vastesaeger.
来源: Rheumatology (Oxford). 2016年55卷11期1946-1953页
To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission.
309. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
作者: Julie Ducreux.;Frédéric A Houssiau.;Pierre Vandepapelière.;Christian Jorgensen.;Estibaliz Lazaro.;François Spertini.;Fabien Colaone.;Camille Roucairol.;Marion Laborie.;Thérèse Croughs.;Géraldine Grouard-Vogel.;Bernard R Lauwerys.
来源: Rheumatology (Oxford). 2016年55卷10期1901-5页
IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNα Abs antibodies (Abs), and gene expression profiling.
310. A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.
作者: Morten Aagaard Nielsen.;Thomas Andersen.;Anders Etzerodt.;Tue Wenzel Kragstrup.;Tue Kruse Rasmussen.;Kristian Stengaard-Pedersen.;Merete Lund Hetland.;Kim Hørslev-Petersen.;Peter Junker.;Mikkel Østergaard.;Malene Hvid.;Søren K Moestrup.;Bent Deleuran.
来源: Rheumatology (Oxford). 2016年55卷10期1871-9页
Co-stimulatory T cell cytokines are important in the progression of RA. This study investigates the interplay between 4-1BB, a disintegrin and metalloprotease-17 (ADAM17) and galectin-9 (Gal-9) in RA.
311. Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks.
作者: Ana M Valdes.;Tina Manon-Jensen.;Abhishek Abhishek.;Wendy Jenkins.;Anne Sofie Siebuhr.;Morten A Karsdal.;Sally Doherty.;Weiya Zhang.;Helen Richardson.;Michael Doherty.;Anne-Christine Bay-Jensen.
来源: Rheumatology (Oxford). 2016年55卷9期1642-6页
Recurrent flares constitute the main clinical burden of gout. Our aim was to assess whether biomarkers measuring MMP tissue degradation could be used as markers of frequent gout flares.
312. The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.
作者: Nicole P C Konijn.;Lilian H D van Tuyl.;Maarten Boers.;Peter M van de Ven.;Debby den Uyl.;Marieke M Ter Wee.;Pit Kerstens.;Alexandre E Voskuyl.;Dirkjan van Schaardenburg.;Willem F Lems.;Michael T Nurmohamed.
来源: Rheumatology (Oxford). 2016年55卷9期1615-22页
To investigate the effect of two different high-dose, step-down prednisolone regimens on body composition in early RA patients after 26 weeks of treatment.
313. Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.
作者: Kanneboyina Nagaraju.;Svetlana Ghimbovschi.;Sree Rayavarapu.;Aditi Phadke.;Lisa G Rider.;Eric P Hoffman.;Frederick W Miller.
来源: Rheumatology (Oxford). 2016年55卷9期1673-80页
To identify muscle gene expression patterns that predict rituximab responses and assess the effects of rituximab on muscle gene expression in PM and DM.
314. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
作者: Chingching Foocharoen.;Kitti Chunlertrith.;Pisaln Mairiang.;Ajanee Mahakkanukrauh.;Siraphop Suwannaroj.;Suwassa Namvijit.;Orathai Wantha.;Ratanavadee Nanagara.
来源: Rheumatology (Oxford). 2017年56卷2期214-222页
Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc. The aim of this study was to compare the efficacy of omeprazole in combination with domperidone vs in combination with algycon in reducing the severity and frequency of reflux symptoms of PPI partial response (PPI-PR) GERD in SSc.
315. Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy.
作者: Maria I Ramos.;Marcel B M Teunissen.;Boy Helder.;Saida Aarrass.;Maria J H de Hair.;Arno W van Kuijk.;Danielle M Gerlag.;Paul P Tak.;Maria C Lebre.
来源: Rheumatology (Oxford). 2016年55卷9期1575-84页
We aimed to investigate the early changes in expression of C-type lectin domain family 9, member A (CLEC9A), a C-type lectin that is specifically expressed by the CD141(+) dendritic cell subset that is involved in cross-presentation to CD8(+) T cells, by evaluating gene and/or protein expression in three different compartments [skin, synovial tissue (ST) and serum] after short-term adalimumab treatment in PsA patients compared with placebo.
316. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.
作者: Torbjörn Kullenberg.;Malin Löfqvist.;Mika Leinonen.;Raphaela Goldbach-Mansky.;Hans Olivecrona.
来源: Rheumatology (Oxford). 2016年55卷8期1499-506页
Anakinra is approved for the treatment of RA and cryopyrin-associated periodic syndromes (CAPS). While the anakinra safety profile is well established in RA, the long-term safety profile in severe CAPS is less well documented and will therefore be discussed in this report.
317. Erosive and osteoarthritic structural progression in early rheumatoid arthritis.
作者: Daniel F McWilliams.;Michelle Marshall.;Keeranur Jayakumar.;Sally Doherty.;Michael Doherty.;Weiya Zhang.;Patrick D W Kiely.;Adam Young.;David A Walsh.
来源: Rheumatology (Oxford). 2016年55卷8期1477-88页
To investigate factors associated with joint damage in early RA, and how comorbid OA might influence patient assessment and outcomes.
318. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
作者: Nathan Vastesaeger.;Abraham Garcia Kutzbach.;Howard Amital.;Karel Pavelka.;María Alicia Lazaro.;Robert J Moots.;Jürgen Wollenhaupt.;Cristiano A F Zerbini.;Ingrid Louw.;Bernard Combe.;Andre Beaulieu.;Hendrik Schulze-Koops.;Bhaskar Dasgupta.;Bo Fu.;Susan Huyck.;Haoling H Weng.;Marinella Govoni.;Patrick Durez.
来源: Rheumatology (Oxford). 2016年55卷8期1466-76页
To create a tool to predict probability of remission and low disease activity (LDA) in patients with RA being considered for anti-TNF treatment in clinical practice.
319. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
作者: Paul Emery.;Josef S Smolen.;Arijit Ganguli.;Sebastian Meerwein.;Yanjun Bao.;Hartmut Kupper.;Naijun Chen.;Arthur Kavanaugh.
来源: Rheumatology (Oxford). 2016年55卷8期1458-65页
To evaluate the effects of adalimumab plus MTX (ADA + MTX) vs MTX monotherapy on work-related outcomes in early RA patients with elevated risk of employment loss.
320. Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis.
作者: Anne A Schouffoer.;Florus J van der Giesen.;Liesbeth J J Beaart-van de Voorde.;Ron Wolterbeek.;Tom W J Huizinga.;Theodora P M Vliet Vlieland.
来源: Rheumatology (Oxford). 2016年55卷8期1386-93页
The aim was to assess the validity and responsiveness of the Michigan Hand Questionnaire (MHQ) in patients with SSc.
|